Foghorn Therapeutics (FHTX) Operating Expenses (2019 - 2026)

Foghorn Therapeutics' Operating Expenses history runs 8 years deep, the most recent figure standing at $24.8 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 13.94% year-over-year to $24.8 million; the TTM figure through Mar 2026 stood at $113.3 million (down 6.31% YoY), while the FY2025 annual figure was $117.3 million, down 6.38% from the prior year.
• Operating Expenses was $24.8 million for Q1 2026 at Foghorn Therapeutics, down from $33.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $38.6 million in Q1 2023 to a low of $24.8 million in Q1 2026.
• Historically, Operating Expenses has averaged $32.1 million across 5 years, with a median of $33.1 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses soared 43.07% in 2022, then fell 15.81% in 2025.
• A 5-year view of Operating Expenses shows it stood at $36.1 million in 2022, then decreased by 13.43% to $31.2 million in 2023, then dropped by 13.98% to $26.9 million in 2024, then increased by 23.32% to $33.1 million in 2025, then decreased by 25.01% to $24.8 million in 2026.
• The last three Operating Expenses figures came in at $24.8 million (Q1 2026), $33.1 million (Q4 2025), and $26.7 million (Q3 2025), per Business Quant data.